The Relationship Between BRACCA and MDS on PARP Inhibitors

There was a correlation between BRACCA and development of MDS on PARP inhibitors. Those with germline BRACCA were lower than semantic BRACCA in the risk of AML MDS, he says. But it's those patients who are on more therapy, more platinum, and PARP longers that will be most at risk for developing ML or MDS if they're not well-confident about treatment.